137 related articles for article (PubMed ID: 1551312)
1. The effect of intravenous metformin on glucose metabolism during hyperglycaemia in type 2 diabetes.
Sum CF; Webster JM; Johnson AB; Catalano C; Cooper BG; Taylor R
Diabet Med; 1992; 9(1):61-5. PubMed ID: 1551312
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
Basu R; Shah P; Basu A; Norby B; Dicke B; Chandramouli V; Cohen O; Landau BR; Rizza RA
Diabetes; 2008 Jan; 57(1):24-31. PubMed ID: 17914032
[TBL] [Abstract][Full Text] [Related]
3. Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes.
Hother-Nielsen O; Schmitz O; Andersen PH; Beck-Nielsen H; Pedersen O
Acta Endocrinol (Copenh); 1989 Mar; 120(3):257-65. PubMed ID: 2648723
[TBL] [Abstract][Full Text] [Related]
4. Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue.
Abbasi F; Kamath V; Rizvi AA; Carantoni M; Chen YD; Reaven GM
Diabetes Care; 1997 Dec; 20(12):1863-9. PubMed ID: 9405908
[TBL] [Abstract][Full Text] [Related]
5. Effects of metformin on glucose, insulin and lipid metabolism in patients with mild hypertriglyceridaemia and non-insulin dependent diabetes by glucose tolerance test criteria.
Hollenbeck CB; Johnston P; Varasteh BB; Chen YD; Reaven GM
Diabete Metab; 1991; 17(5):483-9. PubMed ID: 1752350
[TBL] [Abstract][Full Text] [Related]
6. Effect of metformin on hepatic glucose production in Japanese patients with type 2 diabetes mellitus.
Takahara M; Kaneto H; Katakami N; Matsuhisa M; Shimomura I
Endocr J; 2012; 59(9):845-7. PubMed ID: 22673502
[TBL] [Abstract][Full Text] [Related]
7. Association of insulin resistance with hyperglycemia in streptozotocin-diabetic pigs: effects of metformin at isoenergetic feeding in a type 2-like diabetic pig model.
Koopmans SJ; Mroz Z; Dekker R; Corbijn H; Ackermans M; Sauerwein H
Metabolism; 2006 Jul; 55(7):960-71. PubMed ID: 16784971
[TBL] [Abstract][Full Text] [Related]
8. Multiple defects of both hepatic and peripheral intracellular glucose processing contribute to the hyperglycaemia of NIDDM.
Vaag A; Alford F; Henriksen FL; Christopher M; Beck-Nielsen H
Diabetologia; 1995 Mar; 38(3):326-36. PubMed ID: 7758880
[TBL] [Abstract][Full Text] [Related]
9. Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM.
Widén EI; Eriksson JG; Groop LC
Diabetes; 1992 Mar; 41(3):354-8. PubMed ID: 1551495
[TBL] [Abstract][Full Text] [Related]
10. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
[TBL] [Abstract][Full Text] [Related]
11. Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes.
Nosadini R; Avogaro A; Trevisan R; Valerio A; Tessari P; Duner E; Tiengo A; Velussi M; Del Prato S; De Kreutzenberg S
Diabetes Care; 1987; 10(1):62-7. PubMed ID: 3552515
[TBL] [Abstract][Full Text] [Related]
12. Glucose and lipid metabolism in non-insulin-dependent diabetes. Effect of metformin.
Riccio A; Del Prato S; Vigili de Kreutzenberg S; Tiengo A
Diabete Metab; 1991 May; 17(1 Pt 2):180-4. PubMed ID: 1936473
[TBL] [Abstract][Full Text] [Related]
13. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
[TBL] [Abstract][Full Text] [Related]
14. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM.
Jeppesen J; Zhou MY; Chen YD; Reaven GM
Diabetes Care; 1994 Oct; 17(10):1093-9. PubMed ID: 7821127
[TBL] [Abstract][Full Text] [Related]
15. Glucose-mediated glucose disposal in insulin-resistant normoglycemic relatives of type 2 diabetic patients.
Henriksen JE; Levin K; Thye-Rønn P; Alford F; Hother-Nielsen O; Holst JJ; Beck-Nielsen H
Diabetes; 2000 Jul; 49(7):1209-18. PubMed ID: 10909980
[TBL] [Abstract][Full Text] [Related]
16. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.
Nauck MA; Walberg J; Vethacke A; El-Ouaghlidi A; Senkal M; Holst JJ; Gallwitz B; Schmidt WE; Schmiegel W
Regul Pept; 2004 Apr; 118(1-2):89-97. PubMed ID: 14759561
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.
DeFronzo RA; Barzilai N; Simonson DC
J Clin Endocrinol Metab; 1991 Dec; 73(6):1294-301. PubMed ID: 1955512
[TBL] [Abstract][Full Text] [Related]
18. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
Cuthbertson J; Patterson S; O'Harte FP; Bell PM
Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
[TBL] [Abstract][Full Text] [Related]
19. Influence of hyperglycemia on insulin's in vivo effects in type II diabetes.
Revers RR; Fink R; Griffin J; Olefsky JM; Kolterman OG
J Clin Invest; 1984 Mar; 73(3):664-72. PubMed ID: 6368585
[TBL] [Abstract][Full Text] [Related]
20. Effect of masoprocol on carbohydrate and lipid metabolism in a rat model of Type II diabetes.
Reed MJ; Meszaros K; Entes LJ; Claypool MD; Pinkett JG; Brignetti D; Luo J; Khandwala A; Reaven GM
Diabetologia; 1999 Jan; 42(1):102-6. PubMed ID: 10027587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
